Skip to main content
Fig. 8 | BMC Medical Genomics

Fig. 8

From: Identification and validation of a novel predictive signature based on hepatocyte-specific genes in hepatocellular carcinoma by integrated analysis of single-cell and bulk RNA sequencing

Fig. 8

Potential role of the risk score in mutation and drug therapy. (A) Frequency of somatic mutation in different risk groups. (B) Survival analysis of the tumor mutation burden. (C) Subgroup survival analysis of the tumor mutation burden and the risk score. (D) Sensitivity analysis to chemotherapy and targeted therapy in different risk groups (including sorafenib, 5-fluorouracil, doxorubicin, mitomycin C, bortezomib, and vinblastine). The above P < 0.05 was considered statistically significant

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us